Amyloid β aggregation inhib 
Welcome,         Profile    Billing    Logout  
 1 Company  1 Product   1 Product   2 Diseases   1 Trial   8 News 


12345678910111213...2829»
  • ||||||||||  Exploring chemical reactions to induce secondary light-switching response of rhenium(I) dipyridophenazine complex (In-person; Hall B, Room 1 (Ernest N. Morial Convention Center)) -  Mar 12, 2024 - Abstract #ACSSp2024ACS_Sp_12148;    
    Analyzing photochemical products of [Re(CO) 3 (dppz)(Py)] + and DMS reaction using mass spectrometry and nuclear magnetic resonance spectroscopy indicated that the secondary light-switching response was caused by photochemical modification of [Re(CO) 3 (dppz)(Py)] + . In this presentation, we will discuss the possible photochemical reaction of the dppz ligand with DMS.
  • ||||||||||  Targeting Alzheimer's disease with H2S-releasing peptide frameworks: A multifaceted approach (Virtual; Virtual Session (Virtual Only)) -  Mar 12, 2024 - Abstract #ACSSp2024ACS_Sp_11458;    
    These peptide conjugates target multiple factors responsible for the progression of AD, including the reduction of oxidative stress, the inhibition of A? aggregation, and the elevation of ACh levels in a genetically modified C. elegans model expressing human A?.
  • ||||||||||  Computational study of polyphenols as treatment for Alzheimer's Disease | Poster Board #1821 (In-person; Poster Board #1821; Hall C (Ernest N. Morial Convention Center)) -  Mar 12, 2024 - Abstract #ACSSp2024ACS_Sp_9878;    
    peptides in each segment, driving down the ?-sheet content and destabilizing aggregates more compared to Myricetin. More analysis of the additional thirteen polyphenols is in progress as well as comparing results with A?(1-40), a shorter length of A?.
  • ||||||||||  Metal displacement studies with beta-amyloid: One metal to rule them all (Hybrid; Room 353 (Ernest N. Morial Convention Center)) -  Mar 12, 2024 - Abstract #ACSSp2024ACS_Sp_8252;    
    Our research involves the use of fluorescence spectroscopy and anisotropy, UV-Vis spectroscopy, and TEM imaging to shed light on the interactions between metal ions and A?, as well as their aggregation or disaggregation. Our aim is to investigate the role of these metals in peptide aggregation.
  • ||||||||||  Journal:  Amyloid Beta-Mediated Neurovascular Toxicity in Alzheimer's Disease. (Pubmed Central) -  Mar 5, 2024   
    Thus, understanding the cellular and molecular mechanisms of A?-induced neurovascular toxicity is crucial for determining normal and diseased brain function. This chapter discusses the components of NVU, neurovascular uncoupling, A?-induced cerebrovascular reactivity, and cerebral blood flow reduction in neurodegenerative disorders, with special emphasis on Alzheimer's disease.
  • ||||||||||  Review, Journal:  Recent progresses in natural based therapeutic materials for Alzheimer's disease. (Pubmed Central) -  Mar 4, 2024   
    It delves into various intelligent drug delivery systems, encompassing pH and thermo-triggered mechanisms, polymeric and lipid carriers, inorganic nanoparticles, and other vectors. The discussion synthesizes existing knowledge and underscores the transformative impact of these biomaterials in devising innovative strategies, augmenting current therapeutic methodologies, and shaping new paradigms in the realm of Alzheimer's disease treatment.
  • ||||||||||  Journal:  Cystatins: unravelling the biological implications for neuroprotection. (Pubmed Central) -  Feb 28, 2024   
    Cystatin isolated from chicken egg white, called ovocystatin, has been widely used in medical and pharmaceutical research due to its structural and biological similarities to human cystatin C. This article focuses on the potential use of cystatins, with special emphasis on easily obtained ovocystatin, in the treatment of neurodegenerative diseases, such as dementia. The current evidence on cystatin use has shed light on its mechanisms of action and therapeutic implications for neuroprotection and maintenance of cognitive functions.
  • ||||||||||  Journal:  Abalone peptide increases stress resilience and cost-free longevity via SKN-1-governed transcriptional metabolic reprogramming in C. elegans. (Pubmed Central) -  Feb 14, 2024   
    Further investigation reveals that AbaPep#07 can induce transcriptional activation of immune defense, lipid metabolism, and metabolic detoxification pathways, including many SKN-1/Nrf target genes. Together, our findings demonstrate that AbaPep#07 is able to boost stress resilience and reduce behavioral frailty via SKN-1/Nrf-governed transcriptional reprogramming, and provide an insight into the health-promoting potential of antioxidant cryptides as geroprotectors in aging and associated conditions.
  • ||||||||||  Review, Journal:  Extra-Virgin Olive Oil in Alzheimer's Disease: A Comprehensive Review of Cellular, Animal, and Clinical Studies. (Pubmed Central) -  Feb 14, 2024   
    The human studies cited reveal a consistent trend where the consumption of olive oil is associated with cognitive benefits and a decreased risk of AD and related dementias. In conclusion, EVOO and its phenolic compounds hold promising potential for the prevention and treatment of AD, representing a significant shift towards more effective strategies against this complex neurodegenerative disorder.
  • ||||||||||  Review, Journal:  Chiral nanomaterial-based approaches for diagnosis and treatment of protein-aggregated neurodiseases: current status and future opportunities. (Pubmed Central) -  Feb 9, 2024   
    This review covers the origin of chirality in amyloid fibrils and nanomaterials and different chiral detection methods; furthermore, different chiral nanosystems such as chiral plasmonic nanomaterials, chiral carbon-based nanomaterials, and chiral nanosurfaces, which have been used so far for different therapeutic applications against protein-aggregated diseases, are discussed in detail. The findings from this review may pave the way for the development of novel approaches using chiral nanomaterials to combat diseases resulting from protein misfolding and can further be extended to other disease forms.
  • ||||||||||  hyoscine butylbromide oral / Generic mfg.
    Journal:  Design, Synthesis, and Biological Investigation of Quinazoline Derivatives as Multitargeting Therapeutics in Alzheimer's Disease Therapy. (Pubmed Central) -  Feb 8, 2024   
    Additionally, compound AV-2 significantly ameliorated scopolamine and A?-induced cognitive impairments in the in vivo behavioral Y-maze and Morris water maze studies, respectively...The in silico molecular modeling studies of lead compound AV-2 moreover demonstrated a reasonable binding profile with AChE and BACE-1 enzymes and stable ligand-protein complexes throughout the 100 ns run. Compound AV-2 can be regarded as the lead candidate and could be explored more for AD therapy.
  • ||||||||||  Journal:  Alkaloids from Fritillaria przewalskii (Pubmed Central) -  Feb 7, 2024   
    aggregation activity with IC50 value of 33.1 ?M, AChE activity with IC50 value of 6.9 ?M, and also showed NO release inhibitory acitivity with IC50 value of 32.6 ?M. These findings contribute new multi-target anti-AD agents and embody the chemical diversity of F. przewalskii.
  • ||||||||||  Leqembi (lecanemab-irmb) / Biogen, BioArctic, Eisai
    Review, Journal:  Alzheimer's Disease: The Past, Present, and Future of a Globally Progressive Disease. (Pubmed Central) -  Feb 5, 2024   
    Notably, the FDA-approved Lecanemab signifies a breakthrough, slowing disease progression...Tau aggregation blockers and anti-Tau antibodies offer potential against intracellular tau pathology. The review underscores collaborative efforts to uncover AD's secrets and pave the way for memory preservation.
  • ||||||||||  Review, Journal:  Using Neuroimaging to Study Cerebral Amyloid Angiopathy and Its Relationship to Alzheimer's Disease. (Pubmed Central) -  Feb 2, 2024   
    In this review, we will discuss neuroimaging modalities that can be used to investigate markers associated with CAA that may impact AD vulnerability including hemorrhages and microbleeds, blood-brain barrier permeability disruption, reduced cerebral blood flow, amyloid and tau accumulation, white matter tract disruption, reduced cerebrovascular reactivity, and lowered brain glucose metabolism. We present possible areas for research inquiry to advance biomarker discovery and improve diagnostics.
  • ||||||||||  Journal:  M13 phage grafted with peptide motifs as a tool to detect amyloid-? oligomers in brain tissue. (Pubmed Central) -  Feb 1, 2024   
    Similarly, the bacteriophages reveal the presence of such small A?-aggregates in post-mortem hippocampus tissue of AD-patients. These results advocate bacteriophages displaying A?-peptides as a convenient and low-cost tool to identify A?-oligomers in post-mortem brain tissue of AD-model mice and AD-patients.